Internal and Emergency Medicine (2019) 14:85–102
https://doi.org/10.1007/s11739-018-1874-2

EM ORIGINAL

Guidelines for the management of osteoporosis and fragility fractures

Ranuccio Nuti[1] · Maria Luisa Brandi[2] · Giovanni Checchia[3] · Ombretta Di Munno[4] · Ligia Dominguez[5] · Paolo Falaschi[6] · Carmelo Erio Fiore[1] · Giovanni Iolascon[3] · Stefania Maggi[6] · Ra• aella Michieli[7] · Silvia Migliaccio[2] · Salvatore Minisola[1] · Maurizio Rossini[4] · Giuseppe Sessa[8] · Umberto Tarantino[8] · Antonella Toselli[7] · Giovanni Carlo Isaia[5]

Received: 20 April 2018 / Accepted: 6 May 2018 / Published online: 13 June 2018
© The Author(s) 2018

Abstract

Keywords

Inter-Society Commission for Osteoporosis

Definition

Primary osteoporosis

osteogenesis imperfecta,

1 3

Table 1

. D 3 30 40% w 50% ( ) : ö

( ) *Drug osteoporosis* . A ( ), 12 ( ) 70. A w ( ) ( ) w ( ) 2 6 (+2.5 5%), 5 10/.

Epidemiological remarks

3.5 1 ö w 25 -65 25%, w -50 90,000 2010, 70,000 5 8 3 2 10- 9% 1 36% 1 50% ö 20% C 7a 360,000 60% 4%, 1%, 35% ( ). . A . B C D (C), w ( ) C C 11 15/.

Risk factors

( ) *Age*

( ) *Family history of fragility fractures*

( ) *Previous fractures*

( ) *BMD*

( ) *Smoking*

( ) *Immobility*

( ) *Comorbidities*

( ) *Risk factors for falls*

Overall assessment of fracture risk

Diagnosis

Diagnostic imaging



Fig. 1

(50 1/100 w 4

Table 2

C

24

A w (

A

(., %

C ( ): ( ) +0.8 4 - -

Laboratory diagnosis

Bone turnover markers

Genetic evaluation

Non-pharmacological measures for osteoporosis prevention and treatment

Table 3

Nutritional approach

Calcium

Vitamin D

Table 4 25 ( ) D

< 25	< 10	
25 50	10 20	D
50 75	20 30	
75 125	30 50	
125 375	50 150	
> 375	> 150	

1. A ;
2. A ;
3. (500 500) 37 44.

(< 4000 /) 25 ( ) D 25 ( ) D 3 6) 25 ( ) D 30 50 / (75 125 /),

Vitamin D supplementation

D 25 ( ) D. 1 ( ) D D

100,000 25 ( ) D, D_3 D_2 D 25 ( ) D, 50,000 2 3 2,000 A D (1), D,

25 ( ) D_3, 25 ( ) D, 25- (., 25-), ; ( ) 1-25 ( ) $_2D_3$ 1 (., 1 1- D. 1 25 ( ) D3 45 54.

Other nutrients

A (1.0 1.2 / / 20 25 ( ) - B6, B12

Physical activity

:

1.
2.

B D.

30),

25 ( )D 55 64

Prevention of falls

D,

A

Integrated approaches for secondary prevention of fractures

D A, 80% ( ), 1 50%

65 70.

Drug intervention

Pharmacological thresholds

D A T-

B D. 10- A D A 5 /

Anti-osteoporotic drugs

( ) A 79,),

Anti-catabolic drugs

Bisphosphonates B (B) w . B 0.5 5% (CC < 30 /),

B

800 / (100 / 200 2)

(w) 35 / 75 2 /) B D. 2.5 / . A 150 / 3 /3 (5 / /) 3 A B *osteogenesis imperfecta* (w) A B ,

( ) A : B a 1 3

( ) A (A): (3.2 50 100,000

Duration of bisphosphonate therapy

Denosumab

Hormone replacement therapy (HRT)

Selective oestrogen receptor modulators (SERMs)

[illegible] 23, 71–91].

Anabolic drugs

Teriparatide [illegible] 1–34 [illegible], [illegible] 12 [illegible] B, D [illegible] B [illegible] 10%, [illegible] B, D [illegible] 18 [illegible]. [illegible] (20 µg/[illegible]) [illegible] 24 [illegible]. D[illegible] ([illegible])[illegible].

Dual-action drugs

Strontium ranelate [illegible] 50% [illegible].

[illegible] D [illegible] (D[illegible])[illegible] [92–94].

Kyphoplasty and vertebroplasty

[illegible] 1–3 [illegible] fi[illegible]. [illegible] [23, 95, 96].

Compliance with ethical standards

Conflict of interest [illegible].

Statement of human and animal rights

Informed consent

Funding

Open Access

References

1. (2001) D . A 285:785 795
2. , A , B (2014) 25:1439 1443
3. , B , B (2014) C 25:2359 2381
4. A A (2013) 44:40 46
5. , B (2015) 11:98 109
6. (2010) A 2010 ( ) 62:1515 1526
7. (2012) C A 41:595 611
8. B, B, , , D (2015) C B 2015:413169. :// f /10.1155/2015/413169
9. C , C , C (2014) C 89:888 895
10. B D (2015). :// A 2018
11. (2006) 17:237 244
12. A, (2013) . A ( ) A (A). A 8:137
13. C C (1997) . A 103( ):1 1
14. , B (2010) w 2003 2005. 62:113 118
15. A, (2015) C
16. (2012) A 5- . B 50:85 90
17. D , , A, C (2002) . A 46:3136 3142
18. A (1994) A : 4:368 381
19. A, C (2016) B . B, C D 17:396
20. , A (2014) A ( ) ( ). C B 11:120 122
21. A, A, , C (2008) A 19:385 397
22. , B (2017) A A- . 100:537 549
23. , A , B (2016) 68:1 42
24. A, B , (2013) w 2013 CD C D 16:455 467
25. A, C , (2013) (C ( ). 24:23 57
26. D, , (2017) ( ) D A A C 15:521 531
27. A , B , A B (2016) D . B 92:58 69
28. , D , (2017) w 7:555 591
29. (2003) A 14 (3) 43 55
30. (1996) C B 11:984 996
31. C, C, (2014) (A) D A ö 25:953 964
32. D, D, D (2012) (D A) (A). 117:1374 1385
33. (2012) C A 50:799 821

28(4):797 803

69. D C B A D C ( ) (2016) A . B C 2(16):158
70. (2018) : 137
71. A D C C (2011) A 22:2395 2411
72. A B B (2010) 10- : . C 28:561 570
73. C B B (2013) 9:365 374
74. A A D D (2017) C C A A 166:818 839
75. A C V (2012) 432:57 62
76. B D D D (2007) 356:1809 1822
77. C (2007) 357:1799 1809
78. A B (2015) . C A 10:105 115
79. B A B B AB V B (2017) 2017 A C A . A 69(8):1521 1537
80. A (2013) : 52:534 542
81. A A D (2016) D 15:1 32
82. A (2012) C . B 27:227 230
83. B D A B (2014) A : A B B 29:1 23
84. AA A D (2017) ( ) . C D 20:8 24
85. A A (2017) D : A 101:23 30
86. C C (2009) D 361:756 765
87. B C (2008) C 26:4875 4882
88. A C (2012) : . C 6:287 303
89. B, (2009) D 361:745 755
90. B A (2015) D (DA A-): 386:1147 1155
91. AB B DC D D V (2005) : 26:688 703
92. B C (2008) 2 B D B 23:1591 1600
93. B V (2003) (1 34) 18:1932 1941
94. A CD, (2001) (1 34) 344:1434 1441
95. C (2017) A 17:1932 1938
96. A (2016) 20:382 391